Innovent Biologics (01801) reported its 2025 financial results, with revenue reaching RMB 13.04 billion, a year-on-year increase of 38.4%. Net profit attributable to shareholders was RMB 814 million, while non-IFRS profit stood at RMB 1.723 billion, aligning with market expectations. Considering the booking schedule for upfront payments from the company's licensing revenue, the forecast for 2026 net profit attributable to shareholders has been revised downward by 15.3% to RMB 3.37 billion. The 2027 net profit forecast remains largely unchanged at RMB 4.08 billion. An Outperform rating is maintained, supported by a DCF valuation, with a target price of HK$118.3, indicating a potential upside of 38.36% from the current share price.
In 2025, product revenue totaled RMB 11.896 billion, growing 44.6% year-on-year. The flagship product sintilimab demonstrated steady performance, while the comprehensive portfolio—including mazdutide, teptelimab, and tulisokibart—emerged as significant growth drivers. Additionally, out-licensing revenue reached RMB 957 million, becoming a key method for realizing returns on the company's innovation engine.
Since 2025, the company has entered into multiple collaborations: an authorization agreement with Roche for IBI3009, a multi-billion-dollar partnership with Takeda centered on the co-development of IBI363, a New-co collaboration with Ollin around IBI324, and a platform R&D collaboration with Lilly targeting several early-stage molecules. Among these, IBI363, IBI343, and IBI324 are either already in or approaching global Phase III clinical registration stages. According to company announcements, partners estimate the combined potential market size of these three pipelines to exceed USD 60 billion, paving a viable path toward the company's vision of becoming a top-tier global biopharmaceutical enterprise by 2030.
Key catalysts for 2026 will focus on progress in core international pipelines and potential breakthroughs in early-stage molecules. These include: 1) potential first-line data readouts and registration clinical plans for IBI363; 2) development progress of IBI343 in gastric and pancreatic cancers; 3) advancements in IBI3003 and innovative ADC candidates within the oncology segment; and 4) promising developments in the comprehensive portfolio, including IBI302, oral and multi-target GLP-1 therapies, and small nucleic acid pipelines.
Comments